 Time to development of a new, non-HIV related serious adverse event, health related quality of life, the incidence of grade 3 or 4 clinical or laboratory adverse events and changes in virological and immunological markers CD4 cell count, viral load, resistance profiles will vary between the different treatment strategies. 